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Abstract
Background: Tolerability and efficacy of the intestinal phosphate binder Lantharenol® (lanthanum carbonate
octahydrate) were tested in two prospective, randomized and negative controlled laboratory studies with healthy
adult cats fed commercial maintenance diets non-restricted in phosphorus. In the first study, the maximal tolerated
dose was determined. Starting from a dose of 0.125 g/kg body weight mixed with the daily feed ration, the dose
of Lantharenol® was doubled every other week until signs of intolerability were observed (N = 10 cats compared
to 5 untreated controls). In the second study, the effects of feed supplementation for two weeks with
approximately 2, 6, and 20% of the maximal tolerated dose on phosphorus excretion patterns and balance were
assessed (N = 8 cats per group).
Results: Lantharenol® was found to be safe and well tolerated up to the dose of 1 g/kg bodyweight,
corresponding to a concentration of 84 g Lantharenol®/kg complete feed, defined as dry matter with a standard
moisture content of 12%. Feed supplementation for two weeks with approximately 2-20% of this dosage (i.e., 1.6,
4.8, and 16 g/kg complete feed) resulted in a shift from urinary to faecal phosphorus excretion. Apparent
phosphorus digestibility was dose-dependently reduced compared to the control group fed with diet only (N = 8).
Conclusions: The feed additive was well accepted and tolerated by all cats. Therefore, Lantharenol® presents a
well tolerated and efficacious option to individually tailor restriction of dietary phosphorus as indicated, for
instance, in feline chronic kidney disease.
Background
Advances in veterinary medicine and animal nutrition
have increased the life expectancy for companion ani-
mals [1]. This trend has been leading to an increase in
the number of animals developing geriatric diseases,
such as systemic organ disorders like chronic kidney dis-
ease (CKD). Further progress in medical and nutritional
prevention as well as management of systemic organ
disease is therefore required.
Although CKD and ensuing renal failure occur in cats
of all ages, the prevalence of this disease increases with
age [2]. CKD is diagnosed in 2-20% of all cats at some
time of their life, and up to 31% of cats older than 15
years are affected [3]. In the majority of cases the under-
lying cause of CKD remains unknown. However, the
resulting pathophysiology leads to a common endpoint
of irreversible nephron damage. Cats may maintain a
relatively stable state for a variable length of time. In
most cases, CKD will progress to end-stage renal failure
due to the self-perpetuating nature of the disease with
an inherent progressive decline in renal function [4-6].
Distinct clinical signs and pathological changes in
laboratory data are not usually present until more than
80-85% of all nephrons have lost their function [6]. At
this stage, management of the CKD patient is aimed
mainly at reducing clinical signs and slowing progres-
sion of the disease, if possible. Dietary modification is
the mainstay of intervention [7,8]. It is generally
designed to improve the quality and length of life, to
assure an adequate intake of energy, and to minimize
disturbances in fluid, electrolyte, vitamin, mineral, and
acid-base balance [1,7]. It thereby can increase survival
and decrease uremic crises, but in naturally occurring
CKD it is not yet proven that disease progression itself
is slowed by diet.
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Although standard feline maintenance diets contain a
high level of phosphorus (P) which is not a health risk
in animals with normal renal function, retention and
overload of P are inevitable consequences of CKD if
intake of P is not restricted. Consequently, current
guidelines for the management of CKD consistently
underscore the importance of reducing P intake
[5,7-10]. The restriction can be achieved by feeding a
specially formulated diet, by adding an intestinal phos-
phate binder or by combining both approaches. Because
protein sources of animal origin are particularly rich in
digestible P, a low level of P in dietary formulations can
only be achieved through restriction of protein. Unfortu-
nately, diets with reduced protein content are often less
palatable for cats, thus reducing compliance of animals
to consume, and of their owners to feed the diets [8,11].
It is, however, of primary importance that cats with
CKD maintain an adequate intake of nutrients and
energy, and the restriction of dietary protein has to be
carefully weighed against the risk of malnutrition [7].
Thus, P restriction with simultaneous maintenance of
the standard protein level seems to be preferable in the
early stages of CKD.
Phosphorus binding agents do not change dietary
composition and supply, but rather decrease the gastro-
intestinal P absorption. Several calcium or aluminium
based agents available for human use are described in
protocols for the management of CKD in dogs and cats
[2,8-10]. Although the risk and occurrence of side
effects using these agents has been well documented for
human patients, such evidence from studies conducted
in companion animals is rare.
Lantharenol® (lanthanum carbonate octahydrate) is a
new intestinal P binder for animals. It is registered as a
zootechnical feed additive by the European Commission
[12]. The present article reports on its tolerability and
efficacy in healthy cats fed standard feline maintenance
diets non-restricted in phosphorus or protein.
Two independent studies were performed. In the first
one, the dose of Lantharenol® was escalated to identify
the maximum dose that is accepted and tolerated by
cats without causing any adverse effects. The objective
of the second study was to establish a dose-effect rela-
tionship on P digestibility. Both studies were prospec-
tive, randomized, non-masked, negative-controlled
laboratory studies.
Results
Study 1: Dose escalation study
Lantharenol® administered in feed was well accepted by
all of the cats up to a dose of 1 g/kg body weight. At
this dose, only one cat left residuals of about 25% of its
ration on two days out of the 2-week feeding period, yet
still without signs of intolerability. Adverse effects were
first observed when the amount of Lantharenol® was
increased to 2 g/kg body weight. The signs consisted of
repeated vomiting of feed and occurred in seven out of
the ten cats tested, starting on the second day of feeding
the high dose (i.e., on study day 56), accompanied by
refusal of test feed in three cats (see Table 1). Vomiting
ceased after discontinuation of test item administration
for two days (study days 59 and 60), but was observed
again on the second day of re-challenge (study day 62),
confirming the relationship of the adverse event to the
test dose of Lantharenol®. No other signs of systemic or
local gastrointestinal intolerability were observed in
either treated or untreated cats.
Apart from vomiting and reduced feed acceptance at
the highest feed concentration of Lantharenol®, the gen-
eral health status and characteristics of faeces were nor-
mal in all cats. During the physical examinations, no
relevant signs of diseases were observed in any of the
cats.
The average body mass during the study did not differ
between groups (F1,13 = 0.07, NS, see Figure 1A). Over
the course of the study, body mass slightly increased
similarly in the two groups of cats (Study day: F5,65 =
5.43, p < 0.0003; Study day by Group interaction: F5,65 =
0.49, NS). The average serum phosphate levels were
similar between the two groups of cats (F1,13 = 1.96, NS;
see Figure 1B) and levels remained stable across all
tested doses (Study day: F5,65 = 1.93, NS; Study day by
Group interaction: F5,65 = 0.94, NS). Results are shown
in Table 2.
Study 2: Dose-effect study
Feed supplementation with Lantharenol® was well toler-
ated by all animals. No signs of decreased feed accep-
tance or other signs of intolerability were observed in
any group. The results of clinical haematology and of
blood chemistry at baseline and at the end of the study
were within the reference range in all groups (data not
shown).
Serum P levels remained stable and within reference
ranges in all groups with no differences between control
and treatment groups (F3,28 = 0.67, NS; see Table 2).
The mean body mass decreased slightly from baseline
(F1,28 = 239.53, p < 0.0001) and to a similar degree in all
groups (Timepoint by Group interaction: F3,28 = 1.83,
NS; see Figure 2A).
As can be expected with an intestinal P binder, P
excretion in faeces dose-dependently increased (F3,28 =
20.43, p < 0.0001). This effect appeared to be accom-
panied by a corresponding decrease in urinary P excre-
tion (see Figure 2B). This impression, however, was
not confirmed statistically (F3,28 = 1.98, NS), whereas
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post-hoc comparisons pointed to a dose-dependent
decrease.
Accordingly, mean apparent P digestibility was dose-
dependently reduced by feed supplementation with
Lantharenol® (F3,28 = 5.04, p < 0.01; Figure 2C).
Phosphorus balance was not affected by the feeding
Lantharenol-supplemented feed (F3,28 = 0.77, NS; Figure
2D).
Discussion
The beneficial effects of dietary P restriction have been
demonstrated in experimentally induced and in naturally
occurring feline CKD. In cats with surgically reduced
renal mass, dietary restriction of P intake markedly
decreased renal pathology [13]. In a prospective study in
cats with naturally occurring CKD, the mean survival
time of the animals fed a veterinary diet restricted in P
and protein was 2.4 times longer than that of cats main-
tained on a normal non-restricted maintenance diet.
The beneficial effect was mainly attributable to P restric-
tion [11]. In a retrospective study, Plantinga et al. [14]
found similar effects on the survival time of cats fed dif-
ferent renal diets. A low level of dietary P was one of
the main characteristics of the most effective diet.
In a prospective clinical trial, King et al. [15] found a
highly significant negative correlation between plasma P
concentration and survival time. The relevance of serum
P in CKD was further confirmed in a retrospective
study on predictors of survival time: Boyd et al. [16]
found serum P concentration at time of diagnosis to be
the only clinicopathologic variable tested that was pre-
dictive of survival.
Nutritional intervention to restrict P intake is consid-
ered as potentially effective to interrupt the vicious cir-
cle of inherent, progressive decline in renal function. In
particular, the available evidence strongly supports the
notion that this intervention is able to prevent renal sec-
ondary hyperparathyroidism and its sequelae [10,17,18].
A number of kidney friendly diets for cats and dogs spe-
cifically designed to restrict P intake are commercially
available. They have a reduced content of protein and P
and are adapted to further support nutritional needs of
CKD patients. Restriction of protein is an important


























A 0 0 0 0 63 5/0 None
B 0 0 0 0 14 10/0 None
B 0.125 2.7 10.2 0.4 14 10/0 None
B 0.250 5.4 20.5 0.8 14 10/0 None
B 0.500 10.8 41.8 1.5 14 10/0 None
B 1.000 22.1 84.4 3.1 14 9/14 None
B 2.000 44.5 170.2 6.2 45 7/3 Vomiting
The daily consumption, number of treatment days, number of cats accepting the feed and signs of intolerability observed were compared between a
Lantharenol treated group (B; N = 10) and a negative control group (A; N = 5).
1 IAMS adult, rich in lamb, 24% dry matter
2 Complete feed is calculated by multiplying dry matter by the factor 1.12
3 Group means
4 One cat left 25% of its feed on 2 of 14 days
5 The highest dose of Lantharenol® was administered for 2 days, withdrawn for 2 days and then again given for 2 other days (re-challenge)
Figure 1 Body mass and serum phosphate levels in cats
subjected to a fortnightly dose escalation regimen of
Lantharenol® (Study 1). Panel A depicts the body mass (kg),
serum phosphate levels (mmol/L) are shown in panel B as means
and standard deviations of the Lantharenol®-treated and the
untreated control group.
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means to reduce P content because animal protein
sources are intrinsically rich in P. However, the palat-
ability of protein-restricted diets appears to be reduced,
and consequently they are often less well accepted [5].
Dietary protein restriction must be carefully weighed
against the risk of malnutrition and exacerbation of azo-
taemia, particularly in CKD patients where anorexia is
already one of the most common signs.
Regular commercial maintenance diets for cats still
remain relatively rich in P. In addition, the recom-
mended daily requirement of P for adult cats appears to
be overestimated [19]. This is particularly true for older
animals with a reduced renal capacity for P clearance.
With progression of CKD, the degree of P restriction
needs to increase accordingly [8] which is difficult to
achieve by mere restriction of P content in the feed
through protein restriction.
As a potential alternative to dietary P restriction, or as
an aid to further reduce the dietary burden of absorb-
able P beyond the technical and acceptance limits of
restriction, an intestinal P binder can be added to the
feed. Such agents bind diet-borne phosphate in the gas-
trointestinal tract and thereby reduce apparent P digest-
ibility and systemic P availability.
In a recent review on the management of feline hyper-
phosphataemia, seven such P binding agents were listed:
aluminium carbonate, aluminium hydroxide, aluminium
oxide, calcium carbonate (with or without chitosan), cal-
cium acetate, sevelamer hydrochloride, and lanthanum
carbonate [10]. These compounds are derived from
human treatment of renal hyperphosphataemia. With
the exception of Lantharenol® (lanthanum carbonate
octahydrate), none of the P binders listed above has so
far undergone any formal assessment by regulatory
agencies for safety and efficacy as P binders for veterin-
ary use, be it as a feed additive or as a pharmaceutical
drug. Lanthanum carbonate tetrahydrate (Fosrenol®) is
approved as a drug for treating hyperphosphataemia in
human patients with end-stage CKD. Extensive trials
proved that in this target population this P binder has
few side-effects, which were mainly restricted to gastro-
intestinal tolerability [20]. It is an effective agent without
significant risk of hypercalcaemia or worsening meta-
bolic acidosis, and clinical studies in humans have
demonstrated its tolerability for short- and long-term
administration [21].
In the studies reported in the present paper, Lanthare-
nol® was found to be well tolerated and efficacious to
reduce systemic P availability in healthy cats as well. It
was well accepted and tolerated by healthy cats fed stan-
dard moist feline maintenance diets non-restricted in P
and protein. General health status, P balance, feed
acceptance, body weight changes and serum P levels
were used as the main indicators for tolerability and
Table 2 No effects of Lantharenol® on P intake and P serum levels and difference of P serum level with respect to
baseline in healthy adult cats (Study 2)
Measures Dose of Lantharenol® (g/kg feed original moist substance)
0 0.3 1.0 3.0
P intake
Daily mean (mg) 200 ± 51 187 ± 51 230 ± 25 203 ± 48
Serum P levels
Final (mmol/L) 1.28 ± 0.19 1.42 ± 0.23 1.32 ± 0.23 1.32 ± 0.17
Diff. to baseline (mmol/L) -0.04 ± 0.09 0.04 ± 0.20 0.02 ± 0.09 -0.08 ± 0.20
Measures were taken on day -3 (baseline) and on day +14 and are depicted as group means ± standard deviation (N = 8 per group).
Figure 2 Effects of feed supplemented with 0, 0.3, 1 or 3
grams Lantharenol per kg feed original moist substance in
cats (Study 2). Body mass (kg) of four groups of cats fed cat feed
supplemented with 0, 0.3, 1 or 3 grams Lantharenol per kg feed
original moist substance (OS) on day -3 (baseline) and day 14 of the
study (panel A), P excretion with urine and faeces (panel B),
apparent P digestibility (panel C) and P balance (panel D) measured
on day 14 of the study. The means and standard deviations are
depicted per treatment group. Means with the same letter are not
statistically different from one another (post-hoc tests). Note that
the overall effect in urinary P excretion (panel B) was not significant.
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systemic tolerability of Lantharenol® in the range of feed
concentrations tested, whereas the shift of P excretion
from urinary to faecal excretion was used to assess
efficacy.
Supplementation of feed with Lantharenol® produced
no adverse effects on feed acceptance and behaviour up
to a dose of 1 g/kg body weight (corresponding to 84 g/
kg complete feed). During a total of more than 800 indi-
vidual feeding sessions in both studies, feed supplemen-
tation with Lantharenol® was well accepted up to this
maximal tolerated dose.
In the dose escalation study, vomiting first occurred at
a dosage of 2 g/kg body weight in 7 out of 10 cats. As
there had been an overall acceptance of the supplemen-
ted feed in all cats at dosages up to the maximal toler-
ated dose, it is assumed that acute gastrointestinal
irritation and resulting gastrointestinal intolerability is
the limiting factor for Lantharenol® overdosing, consis-
tent with findings reported in studies with Fosrenol® in
human patients [20].
General health status and serum P levels were unaf-
fected within the total dose range of Lantharenol®
applied, including the maximal tolerated dose and
beyond. Furthermore, there were no adverse effects on
P balance, clinical haematology and blood chemistry
values as determined in the dose-effect study.
In all groups including controls, body weights
increased in the dose escalation study, and significantly
decreased in the dose-effect study, even though the
dosage of Lantharenol® amounted to only 2-20% of the
maximal tolerated dose determined and daily feed
intakes were unchanged. The most likely explanation for
the observed weight loss is the inevitably stressful indivi-
dual housing during the three day urine and faeces sam-
pling period. Another possible explanation is that the
cats in the dose-effect study were not fed according to
their actual needs. The energy density was not declared
on the feed label, and ad libitum feeding was recom-
mended by the manufacturer. To avoid potential con-
flicts with nutritional demands, the cats were switched
to this feed about a month before the official acclimati-
sation period to ensure that they were given an appro-
priate daily ration during the study. In any case, an
effect of the test item on body weight can be excluded,
as all groups including the control group that did not
receive Lantharenol® were similarly affected, and feed
intake was not affected by feed supplementation with
Lantharenol®.
Lantharenol® proved to be an effective P binder with a
dose dependent effect. Dosages of 1.6, 4.8 and 16 g/kg
complete feed resulted in a dose related increase in fae-
cal P excretion. This increase appeared to be accompa-
nied by a decrease in urinary P excretion, but statistical
evaluation failed to support this impression. This failure
is likely related to the large standard deviations for urin-
ary P excretion. Part of this variability could potentially
have been overcome by longer sampling times and/or
within subject analysis of changes in P excretion pat-
terns from baseline. However, the experimental design
of the dose-effect study did not foresee a baseline phase
and hence did not allow for a within subject analysis.
Feed supplementation with Lantharenol® reduced
mean apparent P digestibility by up to 22%. Slightly
lower but significant effects were observed with the low-
est dosage tested (-15% mean apparent P digestibility at
1.6 g/kg complete feed). The results of a study by
Wagner et al. [22] showed a similar absolute reduction
of P digestibility in a balance trial with healthy adult
cats fed a commercial canned diet for senior cats sup-
plemented with a formulation of calcium carbonate and
chitosan. Positive effects of this formulation on serum P
and parathyroid hormone levels in cats with surgically
reduced renal mass were also described by Brown et al.
[17]. However, until prospective data on the safety and
tolerability of calcium-based P binders become publicly
available, the risk of hypercalcaemia with vascular and
soft tissue calcification should be considered before
using such agents in nutritional management of CKD in
cats [9,10,23]. In fact, where serum calcium concentra-
tions are elevated, alternative calcium-free P binders are
preferable.
Phosphorus binders based on aluminium have already
been disfavoured for use in CKD because of the poten-
tial for development of aluminium toxicity [10,20,23].
Possible adverse side effects have not yet been systema-
tically evaluated in companion animals, but recently,
two cases of aluminium toxicity following administration
of aluminium-based P binders have been reported in
dogs [24].
Sevelamer hydrochloride (Renagel®), an organic poly-
mer, is a relatively new P binder used in human patients
on renal dialysis. In rats with experimentally induced
CKD, sevelamer significantly inhibited the occurrence of
hyperphosphataemia and protected against deterioration
of renal function, although the mode of action for the
protective effect remains unclear [25]. Its effects in com-
panion animals have not yet been reported to our
knowledge.
Conclusions
The studies reported in the present paper show a statis-
tically significant effect of Lantharenol® on P excretion
and apparent P digestibility from the lowest dosage
tested (1.6 g/kg complete feed). Supplementation of reg-
ular maintenance feed with Lantharenol® was well toler-
ated and accepted by cats up to the dose of 1 g/kg body
weight, corresponding to a concentration of 22 g/kg
feed original moist substance or 84 g/kg complete feed.
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These results indicate a safety margin of more than ten
times the maximal feed concentration of 7.5 g Lanthare-
nol®/kg complete feed approved for cats [12]. Further
studies on Lantharenol® including its efficacy in P-
restricted diets and in cats with CKD, will be published
separately.
Methods
Animals, housing and management (both studies)
All cats included in the studies were adult laboratory
European shorthair cats. They were in good health sta-
tus as determined by physical examination and bio-
chemical and haematological blood values within the
reference ranges. All cats were regularly vaccinated. The
animals had been housed in the test facilities prior to
start of the study. Therefore, the acclimation period
before the first administration of the test item was lim-
ited to two weeks. In this period, the cats were familiar-
ized with the study-specific diet and feeding conditions.
In both studies, the animals were maintained in envir-
onmentally controlled rooms. They were housed in
groups and were confined to individual cages only dur-
ing the daily four hours feeding period and for specimen
collection. Drinking water was supplied ad libitum.
The general health status of the cats and signs of any
untoward effects (e.g. changes in behaviour, adverse
events), as well as individual feed intake and faecal char-
acteristics, were monitored and documented daily
throughout both studies.
The study protocols were designed in compliance with
the national and international guidelines and laws con-
cerning animal welfare. Regarding study 1, permission
to use animals for experimentation was given by District
Council Düsseldorf, Germany, file No. 50.5-240-1-37/01.
Study 2 was ethically approved by Clinvet Animal
Health Ethics Committee, Bloemfontein, Republic of
South Africa. After study completion, all cats returned
to the cat colonies of the test facilities for use in further
studies, unrelated to the present ones.
Study Procedures and Statistical Analyses
Study 1: Dose escalation study
A total of 15 adult (1- to 2-year-old) neutered female
cats were randomly allocated to the study group receiv-
ing Lantharenol® (10 cats) and to the control group fed
the non-supplemented diet (5 cats).
The cats were fed a standard moist feline maintenance
diet (IAMS Adult, Rich in Lamb, IAMS Pet Feed GmbH
& Co, Schwalbach, Germany), containing 24% dry mat-
ter and 0.26% P in the original substance. The daily
ration was adapted to the individual need as determined
during the acclimation period. The amount of uncon-
sumed feed was assessed after finishing the daily feeding
period.
The test item was mixed daily into the individual feed
portions of the Lantharenol® group, starting with a
dosage of 0.125 g/kg body weight on study day 0. The
dosage was doubled every 14 days until signs of intoler-
ability were observed. Cats in the control group were
fed the same diet without any admixture for the entire
duration of the study (see Table 1, first two columns).
Body weights were assessed weekly for tolerability
observations and for calculation of the individual
amount of test item before each dose escalation.
Blood samples for determination of serum P levels
were collected under fasted conditions every 14 days (on
study days -2, 12, 26, 40, and 54, i.e., 2 days before the
next planned dose incrementation) and on day 63 (final
examination). The samples were centrifuged at 4°C with
1800 rpm for 10 minutes and frozen. They were deliv-
ered within 3-4 hours for P determination according to
standard procedures at a clinical laboratory (BIOFO-
CUS, Recklinghausen, Germany).
Repeated physical examinations were performed
according to standard veterinary procedures before, dur-
ing, and at the end of the study. Each animal was exam-
ined to assess the hair coat/skin, gingivae, respiratory
tract, cardiovascular tract, digestive tract, urinary and
reproductive system, musculosceletal system and the
central nervous system.
Signs of intolerability and feed consumption were
documented and reviewed clinically.
Statistical analysis An analysis of the parametric data
of systemic tolerability observations (body weight, serum
P levels) was performed using the SAS® statistical soft-
ware package version 9.2 (SAS Institute, Cary, NC) for
descriptive and exploratory statistical methods. Changes
in body weight and serum P levels were analyzed by
repeated measures ANOVA with the repeated measures
factor ‘Study day’ and the fixed factor ‘Group’ (Lanthare-
nol® treated vs. untreated control). F-values with an
associated probability < 0.05 were considered as statisti-
cally reliable.
Study 2: Dose-effect study
Thirty-two neutered adult (1-3 years old) cats of either
gender were randomly assigned to 4 groups (A-D; N =
8 per group). All animals were fed a commercially avail-
able moist feline maintenance diet (Petley’s Gourmet
Supreme Beef Casserole; 16.9% dry matter, 0.19% P in
original substance) once daily. The daily ration of feed
was adapted to the individual need of the cats. The indi-
vidual daily feed intake was quantified during the accli-
mation period (day -14 to day -1) and during the test
item administration period (day 0 to +13).
Lantharenol® was mixed into the individual daily feed
portions to achieve concentrations of 0 (control, group
A), 0.3 (group B), 1.0 (group C) and 3.0 (group D) g/kg
feed original substance (corresponding to about 1.6, 4.8,
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and 16 g Lantharenol® per kg complete feed, defined by
the European Commission as ‘air-dry’ matter containing
a standard moisture of 12%) over a period of two weeks.
The dose range equated to approximately 2-20% of the
maximal tolerated feed concentration determined in the
dose escalation study.
The animals were monitored for potential signs of
intolerability throughout the study. Body weights were
determined before the start and at the end of the
Lantharenol® administration period (days -3 and +14,
respectively).
Blood specimens were collected under fasted condi-
tions on days -3 and +14. Cats were sedated to facilitate
blood specimen collection (0.125 mL xylazine 2% per kg
body weight intramuscularly; Bayer Animal Health
GmbH). Specimens for clinical chemistry were centri-
fuged and dispatched in a cool box. Analyses were per-
formed according to standard methods (haematology:
ClinVet International Ltd., Bloemfontein, Republic of
South Africa; clinical chemistry: PathCare Veterinary
Laboratory, Belleville, Republic of South Africa). The
samples were analysed to determine the standard full
haemogram and clinical chemistry (including serum
values of urea, creatinine, sodium, chloride, potassium,
P, calcium, total serum protein, albumin globulin, liver
enzymes, total bilirubin, amylase and glucose).
From day +11 through end of study on the morning
of day +14, urine and faeces were collected quantita-
tively from the cat litter boxes. A non absorbent litter
(Katkor, Rein Vet Products, The Netherlands; [26] was
used for separate collection of urine and faeces. The
three 24-hour-samples obtained from each individual
cat during this period were pooled. Urine specimens
were placed on ice and faecal samples were frozen at
-20°C immediately after collection. Samples were then
dispatched in a cool box for the determination of P con-
tent according to standard methods at clinical labora-
tories (urine: PathCare Veterinary Laboratory, Bellville,
Republic of South Africa; faeces: ARC-ANPI Laboratory,
Gauteng, Republic of South Africa).
From these values, as well as from the calculated diet-
ary intake of P (daily feed intake in g × 0.19% P content
in original feed), P balance and apparent digestibility of
P in the feed were calculated with the formula:
Pbalance (g) = P intake− (P excretion with urine + P excretion with faeces)
Apparent digestibility of P(%) = [(P intake− Pexcretion with faeces)÷ P intake]× 100
Per dose of Lantharenol® the individual data of feed
acceptance, adverse events and/or changes in clinical
state, haematology and blood chemistry were tabulated,
and assessed for any values outside the reference ranges.
Statistical analysis Test item dependent changes from
baseline (day -3) to day +14 in body weight and serum P
concentrations within each group and between the groups
were analyzed statistically by repeated measures ANOVA
with dose as fixed effect and time point as repeated mea-
sures factor. Dose effects on P balance, urinary and faecal
P excretion were evaluated by an ANOVA with dosage of
Lantharenol® as the main effect. Post-hoc tests were used
for between group comparisons. The level of statistical sig-
nificance was set to p < 0.05.
Acknowledgements
Ms. H.L. Erasmus and Mr. C.B. Erasmus (employees of Clinvet, Rep. South
Africa) as well as Ms. B. Pommer, Ms. R. Schneider, Ms. M. Dalmus, Ms. S.
Schwarzkopf, Ms. S. Kroeger, Mr. G. Opwis, and Mr. T. Franzen (employees of
Bayer Animal Health at the time of study conduct) are acknowledged for
technical assistance during collection of data. The authors also would like to
express their gratitude to Dr. A. Foster (employee of Bayer Animal Health)
for linguistic check and valuable critical discussion. The funding body (Bayer
Animal Health GmbH) was not involved in the study design, in the
collection, analysis, and interpretation of data, and in the writing of the
manuscript. It however supported the decision of the authors to submit the
manuscript for publication.
Results of these studies have partially been presented earlier as conference
abstracts [27,28]
Author details
1Bayer Animal Health GmbH, Global Drug Discovery & Development,
Building 6700, 51368 Leverkusen, Germany. 2ClinVet International Ltd,
Bloemfontein, Republic of South Africa. 3Faculty of Veterinary Medicine,
University of Leipzig, Germany. 4Emotion and Cognition Group, Farm Animal
Health, University Utrecht, The Netherlands.
Authors’ contributions
The experiments were conceived by BHS, UD, and JMG. They were fully
funded by Bayer Animal Health and performed by the Contract Research
Organisation ClinVet International Ltd, Bloemfontein, Republic of South
Africa (PCD), and in the laboratories of the Sponsor company (UD). FJS
analyzed the data. All authors contributed to, and approved the final
manuscript.
Competing interests
Bayer Animal Health has a financial interest in Lantharenol®®. BHS and UD
are employees of Bayer Animal Health. PCD received compensation as
employee from ClinVet International Ltd for conducting the dose-effect
study and reporting the results, and JMG received compensation as
consultant to Bayer Animal Health GmbH. FJS declares that he has no
competing interests.
Received: 3 October 2011 Accepted: 6 February 2012
Published: 6 February 2012
Pugliese A, Gruppillo A, Die Pietro S: Clinical nutrition in gerontology:
chronic renal disorders of the dog and cat. Vet Res Commun 2005,
29(Suppl. 2):57-63.
2. Rubin SI: Chronic renal failure and its management and nephrolithiasis.
Vet Clin North Am Small Anim Pract 1997, 27:1331-1348.
3. Lulich JP, O’Brien TD, Osborne CA, Polzin DJ: Feline renal failure:
questions, answers, questions. Compend Contin Educ Vet 1992, 14:127-152.
4. Brown SA, Crowell WA, Brown CA, Barsanti JA, Finco DR: Pathophysiology
and management of progressive renal disease. Vet J 1997, 154:95-109.
5. Burkholder WJ: Dietary considerations for dogs and cats with renal
disease. J Am Vet Med Assoc 2000, 216:1730-1734.
6. Grauer GF: Early detection of renal damage and disease in dogs and
cats. Vet Clin North Am Small Anim Pract 2005, 35:581-596.
7. Elliott DA: Nutritional management of chronic renal disease in dogs and
cats. Vet Clin North Am Small Anim Pract 2006, 36:1377-1384.
8. Polzin DJ, Osborne CA, James KM: Medical management of chronic renal
failure in cats: current guidelines. In Consultations in Feline Internal
Medicine. Edited by: August JR. Philadelphia: WB Saunders; 1997:325-336.
Schmidt et al. BMC Veterinary Research 2012, 8:14
http://www.biomedcentral.com/1746-6148/8/14
Page 7 of 8
9. Elliott J: The role of phosphate in chronic kidney disease (CKD)
progression: Part 2. UK Vet J 2008, 13:37-46.
10. Kidder A, Chew D: Treatment options for hyperphosphataemia in feline
CKD. J Feline Med Surg 2009, 11:913-924.
11. Elliott J, Rawlings JM, Markwell PJ, Barber PJ: Survival of cats with naturally
occurring chronic renal failure: effect of dietary management. J Small
Anim Pract 2000, 41:235-242.
12. Kyprianou M: Commission Regulation (EC) No 163/2008 of 22 February
2008 concerning an authorisation of the preparation Lanthanum
carbonate octahydrate (Lantharenol) as a feed additive. Official Journal of
the European Union 2008, , L50: 3-5.
13. Ross LA, Finco DR, Crowell WA: Effect of dietary phosphorus restriction
on the kidneys of cats with reduced renal mass. Am J Vet Res 1982,
43:1023-1026.
14. Plantinga EA, Everts H, Kastelein AMC, Beynen AC: Retrospective study of
the survival of cats with acquired chronic renal insufficiency offered
different commercial diets. Vet Rec 2005, 157:185-187.
15. King JN, Tasker S, Gunn-Moore DA, Strehlau G, the BENRIC Study Group:
Prognostive factors in cats with chronic kidney disease. J Vet Intern Med
2007, 21:906-916.
16. Boyd LM, Langston C, Thompson K, Zivin K, Imanishi M: Survival in cats
with naturally occurring chronic kidney disease (2000-2002). J Vet Intern
Med 2008, 22:1111-1117.
17. Brown SA, Rickertsen M, Sheldon S: Effects of an intestinal phosphorus
binder on serum phosphorus and parathyroid hormone concentration in
cats with reduced renal function. Int J Appl Res Vet Med 2008, 6:155-160.
18. Barber PJ, Rawlings JM, Markwell PJ, Elliott J: Effect of dietary phosphate
restriction on renal secondary hyperparathyroidism in the cat. J Small
Anim Pract 1999, 40:62-70.
19. Kienzle E, Thielen C, Pessinger C: Investigations on phosphorus
requirements of adult cats. J Nutr 1998, 128:2598S-2600S.
20. Freemont AJ: Lanthanum carbonate. Drugs Today 2006, 42:759-770.
21. Joy MS, Kshirsagar A, Candiani C, Brooks T, Hudson JQ: Lanthanum
carbonate. Ann Pharmacother 2006, 40:234-240.
22. Wagner E, Schwendenwein I, Zentek J: Effects of a dietary chitosan and
calcium supplement on Ca and P metabolism in cats. Berl Munch Tierarztl
Wochenschr 2004, 117:310-315.
23. Bleyer AJ: Phosphate binder usage in kidney failure patients. Expert Opin
Pharmacother 2003, 4:941-947.
24. Segev G, Bandt C, Francey T, Cowgill LD: Aluminium toxicity following
administration of aluminium-based phosphate binders in 2 dogs with
renal failure. J Vet Intern Med 2008, 22:1432-1435.
25. Nagano N, Miyata S, Obana S, Kobayashi N, Fukushima N, Burke SK,
Wada M: Sevelamer hydrochloride, a phosphate binder, protects against
deterioration of renal function in rats with progressive chronic renal
insufficiency. Nephrol Dial Transplant 2003, 18:2014-2023.
26. Delport PC, Fourie LJ: Katkor® cat litter, a non-invasive method of
collecting cat urine for phosphate determination. J S Afr Vet Assoc 2005,
76:233-234.
27. Schmidt B, Delport P, Spiecker-Hauser U: A novel Lanthanum-based
phosphate binder decreases intestinal phosphorus absorption in cats. J
Vet Pharmacol Ther 2006, 29(Suppl. 1):206-207.
28. Schmidt B, Spiecker-Hauser U: Overdose acceptance and tolerance of
Lantharenol in adult healthy cats. J Vet Pharmacol Ther 2009, 32(Suppl.
1):129.
doi:10.1186/1746-6148-8-14
Cite this article as: Schmidt et al.: Tolerability and efficacy of the
intestinal phosphate binder Lantharenol®® in cats. BMC Veterinary
Research 2012 8:14.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Schmidt et al. BMC Veterinary Research 2012, 8:14
http://www.biomedcentral.com/1746-6148/8/14
Page 8 of 8
